Detalhe da pesquisa
1.
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Lancet Oncol
; 25(2): 184-197, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38211606
2.
Elongin B promotes breast cancer progression by ubiquitinating tumor suppressor p14/ARF.
Cell Biol Toxicol
; 40(1): 24, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653919
3.
High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
BMC Cancer
; 23(1): 298, 2023 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37005579
4.
A novel eight-gene Immune Cell-Associated Predictive Gene model to predict recurrence in triple-negative breast cancer.
Transl Cancer Res
; 12(7): 1727-1740, 2023 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37588732